Genomic Testing

Questions discussed in this category

Would you use T-DXd as a first-line agent for a patient who developed early metastatic relapse of HER2+ urothelial cancer shortly after standard perioperative chemo/immunotherapy, over other standard non-targeted treatments?

Assuming no other actionable mutations.

2 Answers available

Why does NCCN still not recommend using circulating tumor cells to guide adjuvant chemotherapy in stage II colon cancer when colon cancer experts are currently embracing the practice?

1 Answer available

Would you offer chemotherapy to an elderly patient with MSI-H stage 3 colon cancer who cannot tolerate oxaliplatin?

3 Answers available

Which patients with Stage II-III lung adenocarcinoma, in whom you are considering neoadjuvant chemoimmunotherapy, can you rely on liquid NGS to exclude driver mutations in lieu of repeat tissue biopsy?

Per NCCN exclusion of EGFR/ALK alterations at a minimum is recommended prior to consideration of neoadjuvant chemoimmunotherapy.

1 Answer available

Does cytotoxic chemotherapy affect the yield of germline testing?

Should testing for germline mutations -- eg. saliva sample -- occur before or after the completion of chemotherapy - or the timing does not matter?&nb...

1 Answer available

For patients with resected colon cancer, to what extent would you adapt adjuvant chemotherapy if ctDNA results don't correspond with your initial treatment recommendation?

3 Answers available

How, if at all, are you employing ctDNA in the management of patients with colon cancer?

1 Answer available

Is there any role for re-biopsy and NGS for patients with NSCLC and KRAS G12C at time of progression after first line therapy before starting sotorasib, or after progression on sotorasib?

1 Answer available

Can you use NGS panels or ctDNA to help you find organ of origin in the workup of carcinoma of unknown origin?

If so, what alterations would be helpful to narrow the diagnosis?

1 Answer available

How do you envision genomic scoring systems for pediatric cancers being applied in a real-world setting?

Such as the scoring system described by Summers et al, "Comprehensive Genomic Profiling of High-Risk Pediatric Cancer Patients Has a Measurable Impact...

2 Answers available

Do you feel that more frequent genomic sequencing will be cost-effective in the management of high-risk pediatric cancers?

2 Answers available

What are the perceived implications of broader genomic sequencing as it pertains to interpreting variants of unknown significance and germline predisposition mutations?

Increased genomic testing is likely to increase the frequency with which we encounter these mutations, which we might not otherwise have tested for. H...

3 Answers available

What is your current practice around genomic sequencing for pediatric cancers?

Do you plan to change your practice based on the data presented in this JCO paper by Summers et al?

1 Answer available

Papers discussed in this category

N Engl J Med, 2021 Jun 24

Acquired Resistance to KRAS^G12C Inhibition in Cancer.

JCO Precis Oncol, 2022 Apr

Comprehensive Genomic Profiling ofHigh-Risk Pediatric Cancer Patients Has aMeasurable Impact on Clinical Care

J. Clin. Oncol., 2019 Jan 17

Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary Site.

Mol Diagn Ther, 2023 Apr 26

Validation of a Transcriptome-Based Assay for Classifying Cancers of Unknown Primary Origin.

Transl Oncol, 2021 Jan 16

Machine learning analysis using 77,044 genomic and transcriptomic profiles to accurately predict tumor type.

Lancet Oncol, 2016 Aug 27

Epigenetic profiling to classify cancer of unknown primary: a multicentre, retrospective analysis.

ESMO Open, 2022 Dec 01

Complete genomic characterization in patients with cancer of unknown primary origin in routine diagnostics.

Nat Commun, 2022 Aug 02

Comprehensive genomic and epigenomic analysis in cancer of unknown primary guides molecularly-informed therapies despite heterogeneity.

N Engl J Med, 2022 Jun 04

Circulating Tumor DNA Analysis Guiding Adjuvant Therapy in Stage II Colon Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 May 15

Oxaliplatin in Adjuvant Colorectal Cancer: Is There a Role in Older Patients?

Cancers (Basel), 2021 Jan 15

Prognostic and Predictive Values of Mismatch Repair Deficiency in Non-Metastatic Colorectal Cancer.

J Clin Oncol, 2020 Dec 23

Microsatellite Instability in Patients With Stage III Colon Cancer Receiving Fluoropyrimidine With or Without Oxaliplatin: An ACCENT Pooled Analysis of 12 Adjuvant Trials.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2010-07-10

Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer.

Gastroenterology, 2004-02

Use of 5-fluorouracil and survival in patients with microsatellite-unstable colorectal cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Jan 09

Neoadjuvant Pembrolizumab in Localized Microsatellite Instability High/Deficient Mismatch Repair Solid Tumors.

Nature medicine, 2024 Sep 16

ctDNA-based molecular residual disease and survival in resectable colorectal cancer.

The New England journal of medicine, 2024 Jun 06

Neoadjuvant Immunotherapy in Locally Advanced Mismatch Repair-Deficient Colon Cancer.

Immunotherapy, 2024 Nov 17

ctDNA-guided adjuvant immunotherapy in colorectal cancer.

European journal of cancer (Oxford, England : 1990), 2024 Jun 26

Exploring the biology of ctDNA release in colorectal cancer.

N Engl J Med, 2022 Jun 05

PD-1 Blockade in Mismatch Repair-Deficient, Locally Advanced Rectal Cancer.

Nature medicine, 2024 Sep 15

Neoadjuvant nivolumab and relatlimab in locally advanced MMR-deficient colon cancer: a phase 2 trial.

The New England journal of medicine, 2025 Apr 27

Nonoperative Management of Mismatch Repair-Deficient Tumors.

The New England journal of medicine, 2022 Sep 01

PD-1 Blockade in Mismatch Repair-Deficient Rectal Cancer.

JAMA network open, 2022 Mar 01

Evaluation of Comparative Surveillance Strategies of Circulating Tumor DNA, Imaging, and Carcinoembryonic Antigen Levels in Patients With Resected Colorectal Cancer.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2023 Oct 23

Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Expressing Solid Tumors: Primary Results From the DESTINY-PanTumor02 Phase II Trial.

Related Topics